Published in J Gastroenterol on March 22, 2016
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity (2008) 5.35
Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol (2001) 4.99
Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A (1999) 4.40
Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43
Effect of NKG2D ligand expression on host immune responses. Immunol Rev (2010) 3.08
Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol (2008) 2.53
NKG2D ligands in tumor immunity. Oncogene (2008) 2.26
Tumor-associated MICA is shed by ADAM proteases. Cancer Res (2008) 1.64
Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis. Blood (2007) 1.63
Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood (2010) 1.56
NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res (2009) 1.50
Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol (2013) 1.24
MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells. Cancer Res (2012) 1.23
Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17. Int J Cancer (2013) 1.03
The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells. Front Immunol (2014) 1.02
The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of A disintegrin and metalloproteinases. J Immunol (2010) 1.00
HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines. J Immunol (2012) 1.00
Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer. J Immunol (2013) 0.97
NKG2D signaling in cancer immunosurveillance. Int J Cancer (2014) 0.96
The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J Immunol (2013) 0.96
Inflammation induced by MMP-9 enhances tumor regression of experimental breast cancer. J Immunol (2013) 0.96
Molecular Bases for the Regulation of NKG2D Ligands in Cancer. Front Immunol (2014) 0.94
Importance of NKG2D-NKG2D ligands interaction for cytolytic activity of natural killer cell. Cell Immunol (2012) 0.92
Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. Cancer Res (2009) 0.92
Beyond Stressed Self: Evidence for NKG2D Ligand Expression on Healthy Cells. Curr Immunol Rev (2009) 0.91
NK cell recognition and killing of melanoma cells is controlled by multiple activating receptor-ligand interactions. J Innate Immun (2011) 0.88
Cytokines related to MMP-11 expression by inflammatory cells and breast cancer metastasis. Oncoimmunology (2013) 0.87
Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor. J Immunol (2013) 0.87
MMP9 mediates MICA shedding in human osteosarcomas. Cell Biol Int (2011) 0.82
Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer. Int J Cancer (2014) 0.81
Matrix metalloproteinases in cytotoxic lymphocytes impact on tumour infiltration and immunomodulation. Cancer Microenviron (2010) 0.80
Cell-cell contact activation of fibroblasts increases the expression of matrix metalloproteinases. Ann Med (2006) 0.79
Regulation of NKG2D signaling during the epithelial-to-mesenchymal transition. Oncoimmunology (2013) 0.79
Regulation of NKG2D-ligand cell surface expression by intracellular calcium after HDAC-inhibitor treatment. Mol Immunol (2012) 0.76
Immunohistochemical validation and expression profiling of NKG2D ligands in a wide spectrum of human epithelial neoplasms. J Histochem Cytochem (2014) 0.75
Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer. Int J Cancer (2014) 0.81
HLA class I expression and its alteration by preoperative hyperthermo-chemoradiotherapy in patients with rectal cancer. PLoS One (2014) 0.78
Japanese clinical practice guidelines for congenital biliary dilatation. J Hepatobiliary Pancreat Sci (2017) 0.75
Diagnostic criteria for congenital biliary dilatation 2015. J Hepatobiliary Pancreat Sci (2016) 0.75
Intraperitoneal chemotherapy for gastric cancer with peritoneal disease: experience from Singapore and Japan. Gastric Cancer (2016) 0.75